Nabriva Therapeutics plc (NASDAQ:NBRV) has a beta value of 2.55 and has seen 1,642,092 shares traded in the recent trading session. The company, currently valued at $96.07 Million, closed the recent trade at $0.6728 per share which meant it lost $0 on the day or -3.04% during that session. The NBRV stock price is -311.71% off its 52-week high price of $2.77 and 27.91% above the 52-week low of $0.485. If we look at the company’s 10-day average daily trading volume, we find that it stood at 8.24 Million shares traded. The 3-month trading volume is 6.81 Million shares.
The consensus among analysts is that Nabriva Therapeutics plc (NBRV) is a Hold stock at the moment, with a recommendation rating of 2.8. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 5 out of 6 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.16.
Nabriva Therapeutics plc (NASDAQ:NBRV) trade information
Despite being -3.25% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Jun 25 when the NBRV stock price touched $0.7489 or saw a rise of 10.12%. Year-to-date, Nabriva Therapeutics plc shares have moved -49.01%, while the 5-day performance has seen it change -8.42%. Over the past 30 days, the shares of Nabriva Therapeutics plc (NASDAQ:NBRV) have changed -40.96%. Short interest in the company has seen 6.46 Million shares shorted with days to cover at 0.95.
Wall Street analysts have a consensus price target for the stock at $1.5, which means that the shares’ value could jump 122.95% from current levels. The projected low price target is $1 while the price target rests at a high of $2. In that case, then, we find that the current price level is +197.27% off the targeted high while a plunge would see the stock lose 48.63% from current levels.
Nabriva Therapeutics plc (NBRV) estimates and forecasts
Figures show that Nabriva Therapeutics plc shares have underperformed across the wider relevant industry. The company’s shares have lost -47.49% over the past 6 months, with this year growth rate of -47.32%, compared to 9.3% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 46.7% and 41.7% for the next quarter. Revenue growth from the last financial year stood is estimated to be -46.7%.
3 analysts offering their estimates for the company have set an average revenue estimate of $400Million for the current quarter. 3 have an estimated revenue figure of $650Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $525Million for this quarter, and analysts expect sales will grow by -23.8% for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +31.1% over the past 5 years. Earnings growth for 2020 is a modest +50.6% while over the next 5 years, the company’s earnings are expected to increase by 0%.
Nabriva Therapeutics plc (NASDAQ:NBRV)’s Major holders
Insiders own 1.23% of the company shares, while shares held by institutions stand at 43.41% with a share float percentage of 43.95%. Investors are also buoyed by the number of investors in a company, with Nabriva Therapeutics plc having a total of 67 institutions that hold shares in the company. The top two institutional holders are FMR, LLC with over 6.1 Million shares worth more than $3.51 Million. As of March 30, 2020, FMR, LLC held 6.01% of shares outstanding.
The other major institutional holder is Orbimed Advisors LLC., with the holding of over 4.64 Million shares as of March 30, 2020. The firm’s total holdings are worth over $2.67 Million and represent 4.58% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Advisor Growth Opportunities Fund and Variable Insurance Products Fund III-Growth Opportunities. As of March 30, 2020, the former fund manager holds about 4.38% shares in the company for having 4450981 shares of worth $2.56 Million while later fund manager owns 810.8 Thousand shares of worth $466.21 Thousand as of March 30, 2020, which makes it owner of about 0.8% of company’s outstanding stock.